Intercept Pharmaceuticals, Inc. (ICPT) is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
Moving higher today! Looks like money finding the beaten down names. The last two days have broken out!
Intercept Pharma's Ocaliva Gets FDA Accelerated Approval For Patients With PBC Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on non-viral, progressive liver diseases, announced late Friday that the U.S. Food and Drug Administration or FDA has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis or PBC. The company noted that Ocaliva is the first new medicine for PBC in nearly 20 years. Read full article here: http://www.nasdaq.com/article/inter...approval-for-patients-with-pbc-20160528-00001
Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients - https://finance.yahoo.com/news/intercept-statement-regarding-ocaliva-obeticholic-110500499.html
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc. - https://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-163100642.html
No position yet but up nice today & watching closely >> Intercept Pharmaceuticals, Inc. Was Halved in September, but Presents an Intriguing Opportunity - https://www.fool.com/investing/2017/10/03/intercept-pharmaceuticals-inc-was-halved-in-septem.aspx
cancel above post - got tired of watching it move up and picked up some @ what i thought was a good price but that was before it dropped under $70 so am waiting on it break $72 lol. ER coming up next. Intercept Pharmaceuticals Inc (ICPT) Presents Additional Results From Phase 2 Study of OCA for the Treatment of Patients with PSC - https://www.smarteranalyst.com/2017...lts-phase-2-study-oca-treatment-patients-psc/
You will get that $72 soon enough, this last week keeps looking like its ready , but just a slow drip.
Not enough popping for me just yet & turning into a longer hold than i wanted lol >> Intercept Pops After Topping Third-Quarter Sales, Earnings Views - https://www.investors.com/news/tech...r-sales-earnings-views/?src=A00220&yptr=yahoo PT ranges $69-$112 - https://www.marketbeat.com/stocks/N...m_source=GeneralSocialMedia&utm_medium=Social
still waiting on that $72+ & probably coulda been out long ago if i had focused on playing the ranges, which i will eventually get around to doing b/c need to get rid of a couple bags in my closet sooner or later!! Believe they are presenting data next week & timing for this offering is interesting to say the least... "...The closing of the Concurrent Private Placement is expected to occur on or about April , 2018. 28,546,862 shares (or 28,833,349 shares if the underwriters exercise in full their option to purchase additional shares in this offering) based on an assumed sale price of $62.83, the last reported sale price of our common stock on the Nasdaq Global Select Market on April 3, 2018. Assuming that we sell $120,000,000 in shares of our common stock in this offering and approximately $92.0 million in shares of our common stock in the Concurrent Private Placement, we would receive aggregate gross proceeds of approximately $212.0 million (or approximately $230.0 million if the underwriters exercise in full their option to purchase additional shares in this offering)... Our Chief Executive Officer and certain members of our Board of Directors have indicated an interest in purchasing an aggregate of up to approximately $1.1 million in shares of our common stock in this offering at the price offered to the public and on the same terms as the other purchasers in this offering... https://www.sec.gov/Archives/edgar/data/1270073/000114420418019226/tv489406_424b5.htm
